Current pharmacotherapy and multi-target approaches for Alzheimer's disease
SL Cheong, JK Tiew, YH Fong, HW Leong, YM Chan… - Pharmaceuticals, 2022 - mdpi.com
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by decreased
synaptic transmission and cerebral atrophy with appearance of amyloid plaques and …
synaptic transmission and cerebral atrophy with appearance of amyloid plaques and …
Synthesis of 4-substituted benzyl-2-triazole-linked-tryptamine-paeonol derivatives and evaluation of their selective inhibitions against butyrylcholinesterase and …
JM Oh, Y Kang, JH Hwang, JH Park, WH Shin… - International Journal of …, 2022 - Elsevier
Cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors are being used and
developed to treat Alzheimer's disease (AD), a major type of dementia patients. Fifteen 4 …
developed to treat Alzheimer's disease (AD), a major type of dementia patients. Fifteen 4 …
[HTML][HTML] Analysis of skeletal diversity of multi-target directed ligands (MTDLs) targeting Alzheimer's disease
Alzheimer's disease (AD) remains a significant healthcare challenge, necessitating
innovative therapeutic approaches to address its complex and multifactorial nature …
innovative therapeutic approaches to address its complex and multifactorial nature …
Development of halogenated-chalcones bearing with dimethoxy phenyl head as monoamine oxidase-B inhibitors
NA Rehuman, JM Oh, MA Abdelgawad, EAM Beshr… - Pharmaceuticals, 2022 - mdpi.com
Two series of dimethoxy-halogenated chalcones (DM1–DM20) were synthesized and tested
for their ability to inhibit monoamine oxidase (MAOs). Compound DM2 exhibited the most …
for their ability to inhibit monoamine oxidase (MAOs). Compound DM2 exhibited the most …
[HTML][HTML] A structural approach to investigate halogen substituted MAO-B inhibitors using QSAR modeling, molecular dynamics, and conceptual DFT analysis
Halogenated inhibitors showed robust, reversible, and selective monoamine oxidase-B
(MAO-B) inhibitory efficacy in candidates that were derived from them. Our team has …
(MAO-B) inhibitory efficacy in candidates that were derived from them. Our team has …
Conjugated dienones from differently substituted cinnamaldehyde as highly potent monoamine oxidase-B inhibitors: Synthesis, biochemistry, and computational …
Fifteen multiconjugated dienones (MK1–MK15) were synthesized and evaluated to
determine their inhibitory activities against monoamine oxidases (MAOs) A and B. All …
determine their inhibitory activities against monoamine oxidases (MAOs) A and B. All …
Development of a novel class of pyridazinone derivatives as selective MAO-B inhibitors
Sixteen compounds (TR1–TR16) were synthesized and evaluated for their inhibitory
activities against monoamine oxidase A and B (MAOs). Most of the derivatives showed …
activities against monoamine oxidase A and B (MAOs). Most of the derivatives showed …
Synthetic strategies and medicinal chemistry perspectives of dual acting carbonic anhydrase modulators with monoamine oxidase and cholinesterase inhibitors
S Bindra, EM Mostafa, MA Abdelgawad… - RSC Medicinal …, 2025 - pubs.rsc.org
Multi-target drug design (MTDD) represents the paradigm shift in pharmaceutical research,
moving beyond the conventional one-drug–one-target approach to address the complexity …
moving beyond the conventional one-drug–one-target approach to address the complexity …
3-Phenethyl-2-phenylquinazolin-4 (3H)-one isolated from marine-derived Acremonium sp. CNQ-049 as a dual-functional inhibitor of monoamine oxidases-B and …
JM Oh, PF Hillman, SJ Nam, H Kim - Journal of Applied Biological …, 2023 - koreascience.kr
Isolation of the culture broth of a marine-derived Acremonium sp. CNQ-049 guided by HPLC-
UV yielded compound 1 (3-phenethyl-2-phenylquinazolin-4 (3H)-one), and its inhibitory …
UV yielded compound 1 (3-phenethyl-2-phenylquinazolin-4 (3H)-one), and its inhibitory …